JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Clinical trial NCT06846437 · RECRUITING

Trial details

NCT number: NCT06846437
Sponsor: Shanghai JMT-Bio Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

Start date: 2025-02-18
Primary completion: 2026-10-13
Enrollment: 228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.